Literature DB >> 24027427

Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

Chinthalapally V Rao1, Jagan Mohan R Patlolla, Li Qian, Yuting Zhang, Misty Brewer, Altaf Mohammed, Dhimant Desai, Shantu Amin, Stan Lightfoot, Levy Kopelovich.   

Abstract

Lung cancer is the leading cause of cancer deaths worldwide. Expression of the p53 tumor suppressor protein is frequently altered in tobacco-associated lung cancers. We studied chemopreventive effects of p53-modulating agents, namely, CP-31398 and Prima-1, on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung adenoma and adenocarcinoma formation in female A/J mice. Seven-week-old mice were treated with a single dose of NNK (10 µmol/mouse) by intraperitoneal injection and, 3 weeks later, were randomized to mice fed a control diet or experimental diets containing 50 or 100 ppm CP-31398 or 150 or 300 ppm Prima-1 for either 17 weeks (10 mice/group) or 34 weeks (15 mice/group) to assess the efficacy against lung adenoma and adenocarcinoma. Dietary feeding of 50 or 100 ppm CP-31398 significantly suppressed (P < .0001) lung adenocarcinoma by 64% and 73%, respectively, after 17 weeks and by 47% and 56%, respectively, after 34 weeks. Similarly, 150 or 300 ppm Prima-1 significantly suppressed (P < .0001) lung adenocarcinoma formation by 56% and 62%, respectively, after 17 weeks and 39% and 56%, respectively, after 34 weeks. Importantly, these results suggest that both p53 modulators cause a delay in the progression of adenoma to adenocarcinoma. Immunohistochemical analysis of lung tumors from mice exposed to p53-modulating agents showed a significantly reduced tumor cell proliferation and increased accumulation of wild-type p53 in the nucleus. An increase in p21- and apoptotic-positive cells was also observed in lung tumors of mice exposed to p53-modulating agents. These results support a chemopreventive role of p53-modulating agents in tobacco carcinogen-induced lung adenocarcinoma formation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24027427      PMCID: PMC3769881          DOI: 10.1593/neo.131256

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  44 in total

1.  Pharmacological rescue of mutant p53 conformation and function.

Authors:  B A Foster; H A Coffey; M J Morin; F Rastinejad
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

2.  Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats.

Authors:  Izet M Kapetanovic; Miguel Muzzio; David L McCormick; Thomas N Thompson; William D Johnson; Thomas L Horn; Altaf Mohammed; Chinthalapally V Rao; Levy Kopelovich
Journal:  Cancer Chemother Pharmacol       Date:  2012-05       Impact factor: 3.333

Review 3.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.

Authors:  Zhaohui Peng
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

Review 4.  Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new.

Authors:  Stephen S Hecht
Journal:  Carcinogenesis       Date:  2005-06-01       Impact factor: 4.944

Review 5.  Regulation of p53 in response to DNA damage.

Authors:  N D Lakin; S P Jackson
Journal:  Oncogene       Date:  1999-12-13       Impact factor: 9.867

Review 6.  Therapeutic targeting of p53 by small molecules.

Authors:  Galina Selivanova
Journal:  Semin Cancer Biol       Date:  2010-03-03       Impact factor: 15.707

7.  p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

Authors:  Venkateshwar Madka; Yuting Zhang; Qian Li; Altaf Mohammed; Puneet Sindhwani; Stan Lightfoot; Xue-Re Wu; Levy Kopelovich; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

8.  CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.

Authors:  Xiuwei Tang; Yucui Zhu; Lydia Han; Arianna L Kim; Levy Kopelovich; David R Bickers; Mohammad Athar
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.

Authors:  Chinthalapally V Rao; Malisetty V Swamy; Jagan M R Patlolla; Levy Kopelovich
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

10.  Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.

Authors:  Chinthalapally V Rao; Vernon E Steele; Malisetty V Swamy; Jagan M R Patlolla; Suresh Guruswamy; Levy Kopelovich
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

View more
  9 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.

Authors:  Xing-Xing He; Yu-Nan Zhang; Jun-Wei Yan; Jing-Jun Yan; Qian Wu; Yu-Hu Song
Journal:  Tumour Biol       Date:  2015-08-07

3.  Modulation of cyclins, p53 and mitogen-activated protein kinases signaling in breast cancer cell lines by 4-(3,4,5-trimethoxyphenoxy)benzoic acid.

Authors:  Kuan-Han Lee; Wen-Yueh Ho; Shu-Jing Wu; Hany A Omar; Po-Jui Huang; Clay C C Wang; Jui-Hsiang Hung
Journal:  Int J Mol Sci       Date:  2014-01-08       Impact factor: 5.923

Review 4.  Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Authors:  Maria Ferraiuolo; Lorena Verduci; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-05-03       Impact factor: 5.923

Review 5.  p53 and metabolism: from mechanism to therapeutics.

Authors:  Fernando M Simabuco; Mirian G Morale; Isadora C B Pavan; Ana P Morelli; Fernando R Silva; Rodrigo E Tamura
Journal:  Oncotarget       Date:  2018-05-04

Review 6.  Recent Synthetic Approaches towards Small Molecule Reactivators of p53.

Authors:  Jerson L Silva; Carolina G S Lima; Luciana P Rangel; Giulia D S Ferretti; Fernanda P Pauli; Ruan C B Ribeiro; Thais de B da Silva; Fernando C da Silva; Vitor F Ferreira
Journal:  Biomolecules       Date:  2020-04-20

Review 7.  Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma.

Authors:  Yingming Sun; Zhe Wang; Sufang Qiu; Ruoyu Wang
Journal:  Int J Biol Sci       Date:  2021-03-10       Impact factor: 6.580

Review 8.  Targeting Oncogenic Mutant p53 for Cancer Therapy.

Authors:  Alejandro Parrales; Tomoo Iwakuma
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

9.  Targeting cancer stem cells with p53 modulators.

Authors:  Zhan Zhang; Ling Liu; Roberto Gomez-Casal; Xinhui Wang; Ryo Hayashi; Ettore Appella; Levy Kopelovich; Albert B DeLeo
Journal:  Oncotarget       Date:  2016-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.